FDA Class I Recall: Draeger VentStar Resus Neo Infant Breathing Circuit (October 2026) — Cracks May Restrict Ventilation

FDA Class I Recall: Draeger VentStar Resus Neo Infant Breathing Circuit (October 2026) — Cracks May Restrict Ventilation

Published 2026-10-08 09:33 | Recall and Safety Notice

What Changed

On 2 October 2026, the U.S. Food and Drug Administration (FDA) updated its recall communication for the VentStar Resus Neo breathing circuit, formally classifying Draeger's action as a Class I recall — the most serious category.

On the same page, FDA states that this classification means the device, if it continues to be used, may cause serious injury or even death. This affects hospital-level handling priorities; it is no longer merely a matter of receiving a customer letter.

Comparing the timeline, FDA had already issued an early alert on 3 September 2026, when the issue was listed as a potentially high-risk device problem. The classification was finalized about one month later.

Affected Product and Identification Information

The affected product is VentStar Resus Neo, model MP00310, UDI 04048675422358.

According to the FDA page, this is a single-use breathing circuit intended to deliver respiratory gases from a gas source to infants. Its stated scope of use is infants weighing up to 22 lb (approximately 10 kg).

Such devices are mainly used in critical and emergency settings, where the clinical buffer time is very short. As a result, pre-use inspection is repeatedly emphasized, rather than waiting for alarms to occur before taking action.

Failure Mode and Risk

Draeger states that it has received reports from users who found visible cracks in the circuit before use.

If a cracked circuit is put into use, the circuit may become disconnected or leak, resulting in restricted ventilation or delayed therapy, which may in turn lead to decreased blood oxygen, hypoxia, and in the worst case, patient death.

As of 3 September 2026, Draeger reported zero serious injuries and zero deaths related to this issue. This indicates that the risk has not yet appeared in a concentrated manner in clinical practice, but the classification is still handled at the most serious level.

Actions Required by the Company

On 3 September 2026, the company sent a letter to all affected customers, focusing on two points.

• Inspect the circuit carefully before use for any damage, in accordance with the product instructions for use.
• If cracks or circuit disconnection are found, discard the circuit directly; there is no need to return it to Draeger.

FDA also notes on its page that this recall falls under the category of removing a specific device from the point of use or sale.

Timeline

• 3 September 2026: FDA issued an early alert on this issue.
• 2 October 2026: FDA updated its communication, designating the issue as a Class I recall.

About one month elapsed between the two communications, during which the company completed distribution of the customer letter and preliminary investigation.

Scope and Boundaries

This classification was made by the U.S. FDA and its binding scope is the U.S. market, corresponding to the VentStar Resus Neo distributed by Draeger in the United States.

Specific affected models, lots, and identification information are subject to Draeger's customer letter and the original FDA text. Whether similar products in other countries are covered by the same measure must be verified separately according to local regulatory authority announcements.

Sources and Applicability Notes

Source 1: U.S. Food and Drug Administration (FDA), Breathing Circuit Recall: Draeger Removes VentStar Resus Neo Hoses, https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/breathing-circuit-recall-draeger-removes-ventstar-resus-neo-hoses, published 2 October 2026; the page also records the early alert dated 3 September 2026.

Source 2: FDA Enforcement Report (Event 99787), https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=99787.

Source 3: FDA Medical Device Recall Database (Event 99787), https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?start_search=1&event_id=99787.

Verification scope and access date: This verification accessed the above FDA recall communication page, the Enforcement Report, and the recall database entry, as well as the FDA Medical Device Recalls and Early Alerts list page at https://www.fda.gov/medical-devices/medical-device-safety/medical-device-recalls-and-early-alerts. Access date: 8 October 2026. Product model, UDI, failure mode, required actions, and timeline are taken from the above pages.

Applicability note: This article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company, or registration application. Recall classification, product scope, and required actions are subject to the official original text, and information may change with subsequent official updates.

Information Sources

• U.S. Food and Drug Administration (FDA) — Breathing Circuit Recall: Draeger Removes VentStar Resus Neo Hoses, 2026-10-02
• U.S. Food and Drug Administration (FDA) — Enforcement Report, Event 99787
• U.S. Food and Drug Administration (FDA) — Medical Device Recall Database, Event 99787

AIMEILI Regulatory Interpretation

A Class I recall designation from the U.S. FDA means the agency has determined that use of the affected device may cause serious adverse health consequences or death. It is the most serious recall category and triggers heightened expectations for a manufacturer's recall strategy, health hazard evaluation, public warning, and post-recall reporting under 21 CFR Part 7. The fact that Draeger reported zero serious injuries and zero deaths as of 3 September 2026 does not lower the classification; FDA classifies based on the potential severity of the failure mode, not only on confirmed harm counts.

The approximately one-month gap between the 3 September 2026 early alert and the 2 October 2026 Class I classification is operationally significant. It indicates that FDA reviewed the health hazard and concluded the issue warranted the highest level of risk communication. For manufacturers, this reinforces that corrective and preventive action, customer notification, and field correction planning should not wait for final FDA classification. Early alert status is already a signal to prepare recall documentation, traceability records, and risk communication.

The remedy here is a field correction combining user-level pre-use inspection with discard in place, rather than physical return of the product to the manufacturer. This has practical regulatory consequences: the manufacturer must still maintain recall records, distribution and UDI traceability, effectiveness checks, and close-out reporting, even without product returns. Distributors and hospital customers must also document that the notification was received and that affected inventory was inspected or removed from use.

For global manufacturers and regulatory affairs teams, U.S. Class I classification can influence other jurisdictions. Competent authorities in the EU, Canada, Australia, and other markets may assess whether the same or similar products require vigilance reporting, field safety corrective action, or additional scrutiny. If the same model or a comparable design is distributed outside the United States, regulatory affairs should verify whether the FDA action triggers local reporting obligations under the applicable vigilance and post-market surveillance frameworks.

Finally, the failure mode — visible cracking in an infant breathing circuit — is a design, material, and aging issue that belongs in the risk management file under ISO 14971. Manufacturers of similar circuits should review design verification and validation for crack resistance, shelf life and aging data, packaging and storage conditions, supplier material controls, and complaint trending. A single Class I event in this category often prompts broader review of the product family and its technical documentation.

Business Impact

For hospitals and distributors, the immediate priority is to confirm whether any affected VentStar Resus Neo circuits remain in inventory, quarantine them, and complete the pre-use inspection and discard process described in Draeger's customer letter. Because the remedy does not require physical return, the operational burden shifts to documentation: proof of notification, inspection records, removal from use, and patient safety follow-up where a cracked circuit was identified before use.

For manufacturers, a Class I recall can affect tender eligibility, hospital quality agreements, and supplier qualification status. Procurement teams in critical care settings may request additional evidence of corrective action, updated risk documentation, or alternative supply while the recall is active. Distributors should expect customer inquiries and should coordinate messaging with the manufacturer to avoid inconsistent instructions.

For regulatory affairs and CRO teams supporting device clients, this event is a case study in recall readiness. Recommended actions include reviewing recall SOPs against 21 CFR Part 7 expectations, verifying UDI and distribution records can support rapid traceability, confirming health hazard evaluation procedures, and testing the speed of customer notification. Post-market surveillance and complaint handling systems should be checked for the ability to detect similar cracking trends at an early stage.

Business impact also includes financial and reputational exposure. Recalls involving neonatal and emergency devices attract heightened clinical attention, and the Class I label can extend beyond the U.S. market through global media and regulator attention. Manufacturers should assess recall insurance coverage, stock recovery costs, replacement supply logistics, and potential contractual liabilities with group purchasing organizations and hospital networks. Proactive communication with regulators and customers is generally more effective than reactive handling once the classification becomes public.